Shots:
- Eli Lilly will acquire 3 companies, Curevo, LimmaTech Biologics, & Vaccine Company, to build its infectious disease portfolio through differentiated vaccine & platform technologies
- The deals incl. Curevo’s P-II shingles vaccine candidate amezosvatein, LimmaTech’s P-I vaccine LTB-SA7 targeting S. aureus infections, & Vaccine Company’s preclinical EBV vaccine platform leveraging proprietary in vivo nanoparticle technology
- As per the deals, Lilly will acquire Curevo for ~$1.5B, LimmaTech for ~$780M, & Vaccine Company for ~$1.55B, incl. upfront payments & milestone-based considerations tied to clinical, regulatory, & commercial achievements
Ref: Eli Lilly | Image: Curevo, LimmaTech, & Vaccine Company | Press Release
Related News: Eli Lilly Acquires Engage Biologics for ~$202M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
